ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Positive NSCLC vs. Tagrisso or Vizimpro

dbrock's picture
ASCO 2018 Roundtable
H. Jack West, MD, Founder, President and CEO

Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate Director for Clinical Research at UC Davis Comprehensive Cancer Center, and Sandip Patel - Medical Oncologist and Associate Professor of Medicine at Moores Cancer Center, UC San Diego Health, gathered post meeting to discuss new information from ASCO 2018 regarding lung cancer.

In this roundtable video, the doctors discuss treatment with Tarceva or Tarceva with Avastin as first line therapy for EGFR Positive NSCLC vs. the use of Tagrisso or Vizimpro.

GRACE thanks the following sponsors for their support.

Video Language: 


Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation